{"entity":{"id":"lantern-pharma","kind":"company","name":"Lantern Pharma","aka":["Lantern Pharma Inc.","NASDAQ:LTRN"],"tldr":"Lantern Pharma is a Texas company that uses its RADR machine-learning platform to revive shelved cancer drugs; LP-184 is a DNA-damaging agent activated in tumours with DNA repair defects, including glioblastoma.","summary":"Lantern Pharma applies its RADR artificial-intelligence platform to match small molecules with the tumours and biomarkers most likely to respond. LP-184 is an acylfulvene prodrug activated by the enzyme PTGR1 that causes DNA damage in cells with defective nucleotide excision repair; it is in phase 1 trials in solid tumours and, as LP-184 for glioblastoma, holds orphan and fast track designations. LP-284 targets B-cell lymphomas and LP-300 is in a phase 2 trial in never-smokers with lung adenocarcinoma.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.lanternpharma.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["lp-184"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Dallas, Texas","country":"US","companyType":"biotech","website":"https://www.lanternpharma.com/","ticker":"NASDAQ:LTRN","founded":2013,"stage":"public","investors":[],"funding":[]},"route":"/companies/lantern-pharma/","neighbours":{"drug":[{"id":"lp-184","kind":"drug","name":"LP-184","route":"/drugs/lp-184/"}]}}